nalmefene and Alcohol Abuse

nalmefene has been researched along with Alcohol Abuse in 126 studies

Research

Studies (126)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (7.94)	18.2507
2000's	19 (15.08)	29.6817
2010's	84 (66.67)	24.3611
2020's	13 (10.32)	2.80

Authors

Authors	Studies
Azar, MR; Berzetei-Gurske, I; Cashman, JR; Ghirmai, S; Polgar, WE	1
Azar, MR; Cashman, JR; Ghirmai, S	1
Habu, H; Hashimoto, N; Kishi, Y; Matsuo, K; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Yamada, N	1
Gerhardt, S; Grundinger, N; Karl, D; Kiefer, F; Mann, K; Vollstädt-Klein, S	1
Duprez, R; Hammas, K; Ioannidis, JPA; Laviolle, B; Naudet, F; Palpacuer, C	1
Braillon, A; Naudet, F; Palpacuer, C	1
Brach, BS; Luderer, M; Meulien, D; Mueller, S; Schou, MB; Zhang, D	1
Bumb, JM; Dinter, C; Hermann, D; Karl, D; Kiefer, F; Koopmann, A; Mann, K; Otto, A; Vollstädt-Klein, S	1
Caballeria, E; Gual, A; López-Pelayo, H; Mann, K; Van den Brink, W; Zuluaga, P	1
Hayashi, T; Higuchi, S; Miyata, H	1
Tadori, Y	1
Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Nakamura, I; Takahashi, M; Tsuneyoshi, K	1
Ohgi, Y	1
Tamaki, K	1
Bach, P; Bumb, JM; Dinter, C; Hermann, D; Karl, D; Kiefer, F; Koopmann, A; Mann, K; Vollstädt-Klein, S	1
Andersohn, F; Aubin, HJ; Blin, P; Dureau-Pournin, C; Falissard, B; Micon, S; Paille, F; Pénichon, M; Rigaud, A; Truchi, C	1
Andersohn, F; Borchert, K; Braun, S; Chick, J; Guillo, S; Haas, JS; Kuppan, K; Lemming, OM; Reines, EH; Toussi, M; Tubach, F	1
Gibaja, V; Gillet, P; Labroca, P; Lemarié, J; Martini, H; Paille, F; Petitpain, N; Yéléhé-Okouma, M	1
Franchitto, N; Jullian, B; Pelissier, F; Rolland, B; Salles, J	1
De Filippis, S; De Persis, S; De Risio, L; di Giannantonio, M; Di Nicola, M; Janiri, L; Maremmani, AGI; Maremmani, I; Martinotti, G; Pettorruso, M	1
Carton, L; Gaboriau, L; Lescut, C; Rolland, B	1
Boussageon, R; Duprez, R; Huneau, A; Laviolle, B; Locher, C; Naudet, F; Palpacuer, C	1
Barrio, P; Gual, A; Guardia, J; Ortega, L; Roncero, C; Yuguero, L	2
Aballéa, S; Daeppen, JB; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M	1
Donoghue, K	1
Bernoussi, A; Braillon, A; Taiebi, F	1
Ahmad, SU; Kumar, J; Mohamed, IN; Pakri Mohamed, RM	1
Barrio Giménez, P; Gual, A; Guardia, J; Ortega, L; Roncero, C; Yuguero, L	1
Chaignot, C; Coste, J; Dray-Spira, R; Rey, G; Weill, A; Zureik, M	1
Brix Schou, M; Brotons, C; Castera, P; Großkopf, J; Meulien, D; Steiniger Brach, B; Stewart, E; Zhang, D	1
Alho, H; Castrén, S; Mäkelä, N	1
Hayashi, T; Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Sørensen, P; Takahashi, M; Tsuneyoshi, K	1
Swift, RM	1
Gual, A; He, Y; Mann, K; Torup, L; van den Brink, W	1
Aubin, HJ; Daeppen, JB	1
Franck, J; Jayaram-Lindström, N	1
Keating, GM	1
Soyka, M	3
Heinz, A; Müller, CA	1
Spence, D	1
Batel, P; Chick, J; Gual, A; Kiefer, F; Sinclair, J; Sørensen, P	1
Braillon, A	1
McNulty, SJ; Williams, P	1
Gual, A; Mann, K; Sørensen, P; Torup, L; van den Brink, W	1
Bruguera, P; Gual, A; López-Pelayo, H	1
Barbosa, C; Brodtkorb, TH; Daeppen, JB; François, C; Knight, C; Laramée, P; Rahhali, N; Rehm, J; Toumi, M	1
Aballéa, S; Bineau, S; Chalem, Y; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M	1
Wise, J	1
Borro, P; Leone, S; Testino, G	1
Nubukpo, P	1
Bendimerad, P; Blecha, L	1
Stafford, N	1
Gual, A; Jensen, TJ; Mann, K; Strang, J; Sørensen, P; van den Brink, W	1
Lieb, M; Soyka, M	1
Aubin, HJ; Bladström, A; Chick, J; François, C; Nutt, DJ; Reimer, J; Torup, L	1
Morgan, MY; Pandor, A; Rawdin, A; Rice, P; Stevens, JW; Stevenson, M; Thompson, J	1
Favrod-Coune, T	1
Donnerstag, N; Lüthi, A; Mehlig, A; Raetz Bravo, A; Schneider, T; Taegtmeyer, A	1
Aubin, HJ; Chalem, Y; François, C; Luquiens, A; Rahhali, N; Sørensen, P	1
Baroni, S; Dell'Osso, L; Marazziti, D; Mucci, F; Mungai, F; Piccinni, A; Presta, S	1
Agabio, R; Franconi, F; Gessa, GL; Pani, PP; Preti, A	1
Laramée, P; Rahhali, N; Rehm, J; Roerecke, M; Sørensen, P	1
Bruhn, C	1
Serecigni, JG	1
Dahmke, H; Kullak-Ublick, GA; Kupferschmidt, H; Weiler, S	1
Areberg, J; Faerch, KU; Kyhl, LE; Larsen, F; Li, S; Soegaard, B	1
Sivolap, YP	1
Bellissant, E; Boussageon, R; Laviolle, B; Naudet, F; Palpacuer, C; Reymann, JM	1
Martelli, A; Mattioli, F; Milano, G; Natta, WM; Zavan, V	1
Fontenelle, LF; Piquet-Pessôa, M	1
Bell, M; Brodtkorb, TH; Irving, A; Laramée, P	1
Friede, M; Schnitker, J; Soyka, M	2
Addolorato, G; Bernardi, M; Caputo, F; D'Amore, A; Domenicali, M; Maremmani, AG; Maremmani, I; Zoli, G	1
Bell, M; Brodtkorb, TH; Irving, AH; Laramée, P	1
Dudek, M; Herr, DR; Hytönen, HR; Hyytiä, P; Korpi, ER; Linden, AM; Paasikoski, N; Vashchinkina, E	1
Braillon, A; Granger, B; Naudet, F	1
Angus, K; de Andrade, M; Elders, A; Fitzgerald, N; Heather, N; McCambridge, J; Raistrick, D	1
Aballéa, S; Chalem, Y; Cristeau, O; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M	1
Naudet, F	1
Aballéa, S; Brodtkorb, TH; Cristeau, O; Laramée, P; Millier, A; Montgomery, S; Rahhali, N; Rehm, J; Steeves, S; Toumi, M	1
Boussageon, R; Laviolle, B; Naudet, F; Palpacuer, C	1
Gual, A; Mann, K; Swift, R; Sørensen, P; Torup, L; van den Brink, W; Walker, B	1
Braillon, A; Fitzgerald, N; Naudet, F	1
Carmona, C; Elices, M; Gasol, M; Gasol, X; Martín-Blanco, A; Pascual, JC; Patrizi, B; Soler, J	1
Bolstridge, M; Boyce, M; Breuning Sluth, L; Flechais, RSA; Lingford-Hughes, A; McGonigle, J; Meulien, D; Mick, I; Newbould, RD; Nutt, D; Quelch, DR; Rabiner, E; Ramos, AC; Steiniger-Brach, B; van den Berg, F; von der Goltz, C; Wall, MB; Østergaard Nilausen, D	1
Goh, ET; Morgan, MY	1
Grant, JE; Hollander, E; Kim, SW; Potenza, MN	1
Rösner, S; Soyka, M	2
Hackl-Herrwerth, A; Leucht, S; Rösner, S; Soyka, M; Srisurapanont, M; Vecchi, S	1
Lumbad, J; Yancey, JR	1
Bladström, A; Gual, A; Mann, K; Torup, L; van den Brink, W	1
Anton, RF; Drobes, DJ; Thomas, SE; Voronin, K	2
Salaspuro, M	1
Anthenelli, R; Anton, RF; Bohn, MJ; Galloway, G; Garbutt, J; Gastfriend, D; Johnson, B; Kallio, A; Karhuvaara, S; Kranzler, HR; McCaul, ME; Pettinati, H; Salloum, I; Swift, R; Zweben, A	1
Azar, MR; Costantini, LC; Kleppner, SR; McDonough, J; Patel, R	1
Jarusuraisin, N; Srisurapanont, M	2
Kallio, A; Karhuvaara, S; Löyttyniemi, E; Mäkelä, R; Nurminen, T; Rosberg, M; Simojoki, K; Virta, A	1
Koob, GF; Walker, BM	1
June, HL	1
Goldberg, G; Mantero-Atienza, E; Mason, BJ; Morgan, RO; Ritvo, EC; Salvato, FR; Welch, B	1
Mason, BJ; Salvato, FR	1
O'Malley, SS	1
Mason, BJ	1
Litten, RZ	1
Sinclair, JD	1
Borg, L; Gunduz, M; Ho, A; King, A; Kreek, MJ; Maniar, S; Perret, G; Porter, M; Schluger, JH	1
Cummings, R; Durr, LF; Grey, C; Johnson, A; June, HL; Lawrence, A; Mason, D; McCane, S; Ricks-Cord, A; Warren-Reese, C; Williams, LS	1
Carey, TS; Crews, FT; Garbutt, JC; Lohr, KN; West, SL	1
Cutler, RB; Mason, BJ; Ritvo, EC; Salvato, FR; Williams, LD	1
Anton, RF; Drobes, DJ	1
Brady, KT; Malcolm, R; Myrick, H	1
Anton, RF	1
Borrow, J; O'Leary, G; Weiss, RD	1

Reviews

46 review(s) available for nalmefene and Alcohol Abuse

Article	Year
Safety of nalmefene for the treatment of alcohol use disorder: an update. Expert opinion on drug safety, 2020, Volume: 19, Issue:1 Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Drug Approval; Humans; Naltrexone; Narcotic Antagonists	2020
[Pharmacological profile and clinical findings of nalmefene (Selincro Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2020, Volume: 155, Issue:2 Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials, Phase III as Topic; Humans; Japan; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Rats; Receptors, Opioid, kappa; Receptors, Opioid, mu	2020
Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians. Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:6 Topics: Alcoholism; Analgesics, Opioid; Animals; Drug Interactions; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Substance Withdrawal Syndrome	2017
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction (Abingdon, England), 2018, Volume: 113, Issue:2 Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate; Treatment Outcome	2018
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction. Current drug targets, 2018, Volume: 19, Issue:12 Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans; Naltrexone; Quetiapine Fumarate	2018
Selecting an appropriate alcohol pharmacotherapy: review of recent findings. Current opinion in psychiatry, 2019, Volume: 32, Issue:4 Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapentin; Humans; Naltrexone; Ondansetron; Randomized Controlled Trials as Topic; Treatment Outcome	2019
Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. Drug and alcohol dependence, 2013, Nov-01, Volume: 133, Issue:1 Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Aripiprazole; Flupenthixol; Fluvoxamine; Fructose; Humans; Naltrexone; Piperazines; Psychotropic Drugs; Quinolones; Topiramate	2013
Pharmacotherapy for alcohol dependence: status of current treatments. Current opinion in neurobiology, 2013, Volume: 23, Issue:4 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Taurine	2013
Nalmefene: a review of its use in the treatment of alcohol dependence. CNS drugs, 2013, Volume: 27, Issue:9 Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Humans; Internationality; Naltrexone; Randomized Controlled Trials as Topic	2013
[Nalmefene: a novel pharmacotherapeutic option for alcoholism]. Der Nervenarzt, 2014, Volume: 85, Issue:5 Topics: Alcoholism; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome	2014
Nalmefene for the treatment of alcohol dependence: a current update. The international journal of neuropsychopharmacology, 2014, Volume: 17, Issue:4 Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists	2014
[New treatment options for alcohol dependence]. MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8 Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate	2013
Bad medicine: nalmefene in alcohol misuse. BMJ (Clinical research ed.), 2014, Feb-14, Volume: 348 Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents	2014
Nalmefene and its use in alcohol dependence. Drugs of today (Barcelona, Spain : 1998), 2014, Volume: 50, Issue:5 Topics: Alcoholism; Drug Interactions; Humans; Naltrexone	2014
Treatment of alcohol dependence: recent progress and reduction of consumption. Minerva medica, 2014, Volume: 105, Issue:6 Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking; Contraindications; Craving; Disulfiram; Drugs, Investigational; Europe; Humans; Meta-Analysis as Topic; Multicenter Studies as Topic; Naltrexone; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Sodium Oxybate; Taurine	2014
[Place of the opioid system in biology and treatment of Alcohol Use Disorder]. L'Encephale, 2014, Volume: 40, Issue:6 Topics: Alcoholism; Brain; Craving; Diagnostic and Statistical Manual of Mental Disorders; Dynorphins; Endorphins; Humans; International Classification of Diseases; Naltrexone; Neurotransmitter Agents; Receptors, Opioid	2014
[Benefits in reducing alcohol consumption: how nalmefene can help]. L'Encephale, 2014, Volume: 40, Issue:6 Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Cause of Death; Europe; Female; Humans; Male; Middle Aged; Naltrexone; Risk Factors; Treatment Outcome; Young Adult	2014
[Nalmefene (Selincro) orally]. Journal de pharmacie de Belgique, 2014, Issue:4 Topics: Administration, Oral; Alcohol Deterrents; Alcoholism; Humans; Naltrexone	2014
Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert opinion on drug safety, 2015, Volume: 14, Issue:4 Topics: Adult; Alcohol Drinking; Alcoholism; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome	2015
Recent Developments in Pharmacotherapy of Alcoholism. Pharmacopsychiatry, 2015, Volume: 48, Issue:4-5 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline	2015
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2015, Volume: 33, Issue:8 Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Humans; Naltrexone; Narcotic Antagonists; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Social Support	2015
Nalmefene: A Novel Drug for an Old Disorder. Current medicinal chemistry, 2015, Volume: 22, Issue:27 Topics: Alcohol Drinking; Alcoholism; Animals; Humans; Naltrexone	2015
Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review. European addiction research, 2016, Volume: 22, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Benzodiazepines; Disulfiram; Female; Humans; Male; Naltrexone; Sex Factors; Taurine; Treatment Outcome	2016
Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk. Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:11 Topics: Alcoholism; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Randomized Controlled Trials as Topic	2015
Opioid Receptor Antagonists in the Treatment of Alcoholism. Adicciones, 2015, Sep-29, Volume: 27, Issue:3 Topics: Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists	2015
Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials. PLoS medicine, 2015, Volume: 12, Issue:12 Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome	2015
Opioid antagonists in broadly defined behavioral addictions: a narrative review. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:6 Topics: Alcoholism; Bulimia; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Randomized Controlled Trials as Topic; Trichotillomania	2016
Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:4 Topics: Alcoholism; Animals; Clinical Trials, Phase III as Topic; Harm Reduction; Hospitalization; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic	2016
The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol Dependence. Alcohol and alcoholism (Oxford, Oxfordshire), 2016, Volume: 51, Issue:3 Topics: Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Health Care Costs; Humans; Markov Chains; Models, Economic; Naltrexone; Psychotherapy; Quality-Adjusted Life Years; Treatment Outcome	2016
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis. Pharmacopsychiatry, 2016, Volume: 49, Issue:2 Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome	2016
Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction (Abingdon, England), 2016, Volume: 111, Issue:8 Topics: Alcoholism; Drug Approval; Europe; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Practice Guidelines as Topic; United Kingdom	2016
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-analysis - Comment to Naudet. Pharmacopsychiatry, 2016, Volume: 49, Issue:6 Topics: Alcoholism; Appetite Depressants; Humans; Naltrexone; Narcotic Antagonists	2016
Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2016, Volume: 26, Issue:12 Topics: Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu	2016
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:7 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome	2017
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review. Current drug abuse reviews, 2008, Volume: 1, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, Opioid; Secondary Prevention; Taurine; Temperance; Ventral Tegmental Area	2008
Nalmefene for treatment of alcohol dependence. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:11 Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone	2010
Opioid antagonists for alcohol dependence. The Cochrane database of systematic reviews, 2010, 12-08, Issue:12 Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic	2010
Opioid antagonists for the treatment of alcohol dependence. American family physician, 2011, Nov-01, Volume: 84, Issue:9 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine; Treatment Outcome	2011
[Drug therapy of alcohol dependence--a critical review]. Duodecim; laaketieteellinen aikakauskirja, 2003, Volume: 119, Issue:24 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Topiramate	2003
Opioid antagonists for alcohol dependence. The Cochrane database of systematic reviews, 2005, Jan-25, Issue:1 Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic	2005
Dosing issues in the pharmacotherapy of alcoholism. Alcoholism, clinical and experimental research, 1996, Volume: 20, Issue:7 Suppl Topics: Administration, Oral; Adult; Alcoholism; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Imipramine; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic	1996
Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA, 1999, Apr-14, Volume: 281, Issue:14 Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Lithium; Naltrexone; Narcotic Antagonists; Serotonin Agents; Taurine	1999
Opioid antagonists for alcohol dependence. The Cochrane database of systematic reviews, 2000, Issue:3 Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic	2000
New developments in the pharmacotherapy of alcohol dependence. The American journal on addictions, 2001, Volume: 10, Issue:s1 Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carbamazepine; Drug Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Ritanserin; Serotonin Agents; Sodium Oxybate; Substance Withdrawal Syndrome; Taurine; Valproic Acid; Vigabatrin	2001
Pharmacologic approaches to the management of alcoholism. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 20 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Clinical Trials as Topic; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome	2001
Opioid antagonists in the treatment of alcohol dependence. Current psychiatry reports, 2001, Volume: 3, Issue:6 Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists	2001

Trials

29 trial(s) available for nalmefene and Alcohol Abuse

Article	Year
Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis. Drug and alcohol dependence, 2022, 04-01, Volume: 233 Topics: Alcohol Drinking; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists	2022
The effects of nalmefene on the impulsive and reflective system in alcohol use disorder: A resting-state fMRI study. Psychopharmacology, 2022, Volume: 239, Issue:8 Topics: Alcoholism; Brain Mapping; Cross-Over Studies; Female; Humans; Magnetic Resonance Imaging; Naltrexone	2022
Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis. Alcohol and alcoholism (Oxford, Oxfordshire), 2020, Feb-07, Volume: 55, Issue:1 Topics: Alcohol Drinking; Alcoholism; Elasticity; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome	2020
The effects of nalmefene on emotion processing in alcohol use disorder - A randomized, controlled fMRI study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2019, Volume: 29, Issue:12 Topics: Adult; Aged; Alcoholism; Cross-Over Studies; Double-Blind Method; Emotions; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Photic Stimulation; Psychomotor Performance; Treatment Outcome	2019
Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence. Psychiatry and clinical neurosciences, 2020, Volume: 74, Issue:8 Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Time Factors	2020
Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder. Psychopharmacology, 2021, Volume: 238, Issue:8 Topics: Adult; Alcoholism; Craving; Cross-Over Studies; Cues; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Photic Stimulation; Prospective Studies; Ventral Striatum; Young Adult	2021
Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results. Clinical drug investigation, 2018, Volume: 38, Issue:2 Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Surveys and Questionnaires; Time Factors; Treatment Outcome	2018
A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference? Adicciones, 2019, Sep-01, Volume: 31, Issue:4 Topics: Adult; Alcoholism; Behavior, Addictive; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Risk	2019
Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care. European addiction research, 2018, Volume: 24, Issue:6 Topics: Adult; Alcoholism; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Neuroprotective Agents; Primary Health Care; Psychotherapy; Treatment Outcome; Young Adult	2018
Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial. Psychiatry and clinical neurosciences, 2019, Volume: 73, Issue:11 Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Naltrexone; Risk; Treatment Outcome	2019
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:11 Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome	2013
Can alcohol dependent patients adhere to an 'as-needed' medication regimen? European addiction research, 2014, Volume: 20, Issue:5 Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Self Care; Treatment Outcome	2014
Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:8 Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult	2014
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model. BMJ open, 2014, Sep-16, Volume: 4, Issue:9 Topics: Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Naltrexone; Public Health; Risk Assessment; Social Support	2014
Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. European addiction research, 2015, Volume: 21, Issue:3 Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome	2015
Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report. International clinical psychopharmacology, 2017, Volume: 32, Issue:4 Topics: Adult; Alcoholism; Borderline Personality Disorder; Comorbidity; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Research Report	2017
Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. Biological psychiatry, 2017, 06-01, Volume: 81, Issue:11 Topics: Administration, Intravenous; Adult; Alcoholism; Anticipation, Psychological; Corpus Striatum; Double-Blind Method; Drug Synergism; Ethanol; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Reward	2017
Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology, 2008, Volume: 200, Issue:4 Topics: Adult; Age Factors; Aged; Alcoholism; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gambling; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Psychometrics; Severity of Illness Index; Treatment Outcome; Young Adult	2008
Trial watch: Nalmefene reduces alcohol use in phase III trial. Nature reviews. Drug discovery, 2011, Aug-01, Volume: 10, Issue:8 Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists	2011
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biological psychiatry, 2013, Apr-15, Volume: 73, Issue:8 Topics: Alanine Transaminase; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Female; gamma-Glutamyltransferase; Humans; Liver; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention	2013
A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:4 Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Environment; Female; Humans; Male; Middle Aged; Naltrexone	2003
A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:4 Topics: Adult; Alcoholism; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone	2004
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcoholism, clinical and experimental research, 2004, Volume: 28, Issue:9 Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone	2004
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcoholism, clinical and experimental research, 2007, Volume: 31, Issue:7 Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Finland; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Patient Compliance; Placebos; Sleep Initiation and Maintenance Disorders; Substance Abuse Treatment Centers; Temperance; Treatment Outcome	2007
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcoholism, clinical and experimental research, 1994, Volume: 18, Issue:5 Topics: Alcoholism; Body Weight; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Patient Admission; Pilot Projects; Treatment Outcome	1994
Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject. Alcoholism, clinical and experimental research, 1994, Volume: 18, Issue:5 Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Function Tests; Naltrexone; Narcotic Antagonists	1994
Current strategies for the treatment of alcohol dependence in the United States. Drug and alcohol dependence, 1995, Volume: 39 Suppl 1 Topics: Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome; United States	1995
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Archives of general psychiatry, 1999, Volume: 56, Issue:8 Topics: Administration, Oral; Alcohol Drinking; Alcoholism; Breath Tests; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Temperance; Treatment Outcome	1999
Drinking in alcoholics following an alcohol challenge research protocol. Journal of studies on alcohol, 2000, Volume: 61, Issue:2 Topics: Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Research; Temperance	2000

Other Studies

51 other study(ies) available for nalmefene and Alcohol Abuse

Article	Year
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents. Journal of medicinal chemistry, 2008, Mar-27, Volume: 51, Issue:6 Topics: Alcohol Drinking; Alcoholism; Amides; Animals; Binding, Competitive; Drug Evaluation, Preclinical; Ethanol; Humans; Hydrogen Bonding; Liver; Mice; Microsomes, Liver; Molecular Structure; Morphinans; Naltrexone; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship	2008
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation. Bioorganic & medicinal chemistry, 2009, Sep-15, Volume: 17, Issue:18 Topics: Alcohol Deterrents; Alcoholism; Animals; Humans; Liver; Male; Mice; Naltrexone; Nociceptin Receptor; Protein Binding; Rats; Rats, Wistar; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Structure-Activity Relationship	2009
Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis. BMC medicine, 2019, 09-16, Volume: 17, Issue:1 Topics: Alcohol Drinking; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Research Design	2019
Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption. Psychiatry and clinical neurosciences, 2020, Volume: 74, Issue:3 Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone	2020
Response to 'Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption'. Psychiatry and clinical neurosciences, 2020, Volume: 74, Issue:3 Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone	2020
[Alcohol dependence and opioid receptor -Pharmacological profile of nalmefene]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2020, Volume: 155, Issue:3 Topics: Alcoholism; Animals; Clinical Trials as Topic; Humans; Japan; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid	2020
[Four cases of alcoholic liver cirrhosis in alcohol-dependent patients treated with nalmefene]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2021, Volume: 118, Issue:1 Topics: Alcohol Drinking; Alcoholism; Europe; Humans; Japan; Liver Cirrhosis, Alcoholic; Naltrexone	2021
Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis. Alcohol and alcoholism (Oxford, Oxfordshire), 2021, Aug-30, Volume: 56, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; Female; Humans; Insurance Claim Review; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prospective Studies; Treatment Outcome; Young Adult	2021
Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies. Alcohol and alcoholism (Oxford, Oxfordshire), 2021, Aug-30, Volume: 56, Issue:5 Topics: Adult; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Prospective Studies; Retrospective Studies	2021
Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine. Fundamental & clinical pharmacology, 2017, Volume: 31, Issue:5 Topics: Adult; Aged; Alcoholism; Analgesics, Opioid; Female; France; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pancreatitis; Retrospective Studies; Substance Withdrawal Syndrome	2017
Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study. Advances in therapy, 2017, Volume: 34, Issue:7 Topics: Adult; Alcohol-Related Disorders; Alcoholism; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists	2017
Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:5 Topics: Alcoholism; Antisocial Personality Disorder; Buprenorphine; Heroin Dependence; Humans; Male; Medication Errors; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome	2017
Cost-Effectiveness of Nalmefene Added to Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol-Dependent Patients With High/Very High Drinking Risk Levels: A Microsimulation Model. Journal of studies on alcohol and drugs, 2017, Volume: 78, Issue:6 Topics: Alcohol Drinking; Alcoholism; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Naltrexone; Quality-Adjusted Life Years; Risk	2017
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice? Addiction (Abingdon, England), 2018, Volume: 113, Issue:2 Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate	2018
Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence? Clinical drug investigation, 2018, Volume: 38, Issue:4 Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists	2018
Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence? Clinical drug investigation, 2018, Volume: 38, Issue:4 Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists	2018
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:11 Topics: Acamprosate; Administrative Claims, Healthcare; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Databases, Factual; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Off-Label Use; Risk Assessment; Socioeconomic Factors	2018
Naltrexone and nalmefene: any meaningful difference? Biological psychiatry, 2013, Apr-15, Volume: 73, Issue:8 Topics: Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Secondary Prevention	2013
Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency. BMJ (Clinical research ed.), 2014, Mar-10, Volume: 348 Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone	2014
Bad medicine: using surrogate markers. BMJ (Clinical research ed.), 2014, Mar-10, Volume: 348 Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone	2014
▼Nalmefene for alcohol dependence. Drug and therapeutics bulletin, 2014, Volume: 52, Issue:5 Topics: Alcohol Drinking; Alcoholism; Drug Approval; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prevalence; Sex Factors; United Kingdom	2014
Nalmefene. Alcohol dependence: no advance. Prescrire international, 2014, Volume: 23, Issue:150 Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Patient Safety; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome	2014
A predictive microsimulation model to estimate the clinical relevance of reducing alcohol consumption in alcohol dependence. European addiction research, 2014, Volume: 20, Issue:6 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Computer Simulation; England; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Models, Theoretical; Naltrexone; Narcotic Antagonists; Wounds and Injuries	2014
Decision to recommend drug to cut drink dependence proves controversial. BMJ (Clinical research ed.), 2014, Oct-05, Volume: 349 Topics: Administration, Oral; Adult; Alcoholism; Decision Making; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Selection; Practice Guidelines as Topic; Risk Assessment; State Medicine; Treatment Outcome; United Kingdom	2014
German evaluation says new drug for alcohol dependence is no better than old one. BMJ (Clinical research ed.), 2014, Dec-08, Volume: 349 Topics: Alcohol Deterrents; Alcoholism; Germany; Humans; Naltrexone	2014
[Influence of nalmefene on psychosocial intervention in alcohol-dependent patients]. Revue medicale suisse, 2015, Apr-01, Volume: 11, Issue:468 Topics: Alcohol Deterrents; Alcoholism; Humans; Naltrexone	2015
Severe opioid withdrawal syndrome after a single dose of nalmefene. European journal of clinical pharmacology, 2015, Volume: 71, Issue:8 Topics: Adult; Alcoholism; Analgesics, Opioid; Codeine; Contraindications; Drug Interactions; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome	2015
The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients. PloS one, 2015, Volume: 10, Issue:6 Topics: Adult; Alcohol Drinking; Alcoholism; Demography; Female; Humans; Male; Middle Aged; Naltrexone; Patient Outcome Assessment; Quality of Life; Surveys and Questionnaires; Treatment Outcome	2015
[Reduction of consumption as the first goal of therapy]. Medizinische Monatsschrift fur Pharmazeuten, 2015, Volume: 38, Issue:4 Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists	2015
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions]. Praxis, 2015, Oct-14, Volume: 104, Issue:21 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pharmacovigilance; Substance Withdrawal Syndrome	2015
Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. British journal of clinical pharmacology, 2016, Volume: 81, Issue:2 Topics: Administration, Oral; Alcoholism; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Injections, Intravenous; Models, Biological; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu	2016
[Alcohol use disorders: current approaches to diagnosis and treatment]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:9 Topics: Alcohol Drinking; Alcoholism; Diagnostic and Statistical Manual of Mental Disorders; Ethanol; Female; Humans; International Classification of Diseases; Male; Naltrexone; Narcotic Antagonists; Remission Induction	2015
Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder. Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:1 Topics: Aged; Alcoholism; Disorders of Excessive Somnolence; Fatigue; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists	2016
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series. Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:4 Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Alcohols; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sodium Oxybate; Treatment Outcome	2016
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective. CNS drugs, 2016, Volume: 30, Issue:2 Topics: Adolescent; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost of Illness; Cost-Benefit Analysis; Crime; Efficiency; Female; Health Care Costs; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Naltrexone; Patient Acceptance of Health Care; Psychotherapy; Risk; United Kingdom; Young Adult	2016
Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors. Addiction biology, 2017, Volume: 22, Issue:4 Topics: Alcoholism; Animals; Brain; Disease Models, Animal; Ethanol; Female; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid	2017
Cost-Effectiveness of Nalmefene: Exaggerated Expectations or Fallacy? Alcohol and alcoholism (Oxford, Oxfordshire), 2016, Volume: 51, Issue:5 Topics: Alcoholism; Cost-Benefit Analysis; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome	2016
A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence. Applied health economics and health policy, 2016, Volume: 14, Issue:4 Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Computer Simulation; Europe; Harm Reduction; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Outcome and Process Assessment, Health Care; Public Health; Social Support	2016
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin? Pharmacopsychiatry, 2016, Volume: 49, Issue:6 Topics: Alcoholism; Appetite Depressants; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic	2016
A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence. Clinical drug investigation, 2016, Volume: 36, Issue:11 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Female; Humans; Naltrexone	2016
Evaluation in alcohol use disorders - insights from the nalmefene experience. BMC medicine, 2016, Aug-18, Volume: 14, Issue:1 Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Female; Harm Reduction; Humans; Male; Naltrexone; Narcotic Antagonists	2016
▼Nalmefene-time for last orders? Drug and therapeutics bulletin, 2016, Volume: 54, Issue:9 Topics: Alcoholism; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists	2016
Nalmefene for alcohol dependence: a NICE decision? The lancet. Psychiatry, 2016, Volume: 3, Issue:12 Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Practice Guidelines as Topic; State Medicine; United Kingdom	2016
Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. International journal of pharmaceutics, 2004, Sep-28, Volume: 283, Issue:1-2 Topics: Alcoholism; Animals; Area Under Curve; Delayed-Action Preparations; Equipment Design; Humans; Infusion Pumps, Implantable; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Technology, Pharmaceutical	2004
Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:3 Topics: Administration, Inhalation; Alcoholism; Animals; Central Nervous System Depressants; Conditioning, Operant; Data Interpretation, Statistical; Dynorphins; Ethanol; Injections, Intraventricular; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Self Administration; Substance Withdrawal Syndrome	2008
Preclinical models to evaluate potential pharmacotherapeutic agents in treating alcoholism and studying the neuropharmacological bases of ethanol-seeking behaviors in rats. Current protocols in neuroscience, 2002, Volume: Chapter 9 Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Disease Models, Animal; Drug Evaluation, Preclinical; Ethanol; Female; Male; Naltrexone; Rats; Reinforcement Schedule	2002
International update: new findings on promising medications. Alcoholism, clinical and experimental research, 1996, Volume: 20, Issue:8 Suppl Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Cocaine; Comorbidity; Europe; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Taurine; United States	1996
New treatment options for substance abuse from a public health viewpoint. Annals of medicine, 1998, Volume: 30, Issue:4 Topics: Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Extinction, Psychological; Humans; Naltrexone; Narcotic Antagonists	1998
Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcoholism, clinical and experimental research, 1998, Volume: 22, Issue:7 Topics: Adrenocorticotropic Hormone; Adult; Aged; Alcoholism; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Infusions, Intravenous; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Treatment Outcome	1998
The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcoholism, clinical and experimental research, 1998, Volume: 22, Issue:9 Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Genotype; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains	1998
Nalmefene for alcohol dependence. The Harvard mental health letter, 2000, Volume: 16, Issue:9 Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists	2000